Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 105 | 43 | 61 |
| Samples | 97 | 43 | 53 |
| Peptides | 61 | 24 | 37 |
Function
KRTAP29-1 · Keratin associated like protein 29-1
Predicted to be located in cytosol. [provided by Alliance of Genome Resources, Apr 2022]
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 60 amino-acid changes on canonical ENST00000391353 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in KRTAP29-1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in KRTAP29-1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Gastrointestinal Stromal Tumour | 0/0 0% | 4/133 3% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Burkitts Lymphoma | 3/32 9% | 0/196 0% |
| Germ Cell Tumour | 1/25 4% | 1/169 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Non-Small Cell Lung Carcinoma | 9/304 3% | 2/1390 0% |
| Cervical Carcinoma | 2/35 6% | 0/422 0% |
| Melanoma | 4/210 2% | 5/1899 0% |
| Colorectal Carcinoma | 2/143 1% | 10/3239 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Ovarian Carcinoma | 3/109 3% | 0/998 0% |
| Neuroendocrine Tumour | 2/154 1% | 0/577 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 2/752 0% |
| Pancreatic Carcinoma | 1/89 1% | 3/1611 0% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 0/810 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Non-Cancerous | 1/104 1% | 1/830 0% |
| Gastric Carcinoma | 0/74 0% | 4/1809 0% |
| Neuroblastoma | 3/87 3% | 0/1331 0% |
| Endometrial Carcinoma | 1/42 2% | 0/612 0% |
| Glioma | 0/52 0% | 3/2127 0% |
| Prostate Carcinoma | 1/13 8% | 2/2105 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Other Solid Cancers | 1/94 1% | 1/1515 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 2/1592 0% |
| Bladder Carcinoma | 0/58 0% | 1/956 0% |
| Kidney Carcinoma | 2/85 2% | 0/1862 0% |
| Hepatocellular Carcinoma | 0/46 0% | 2/2210 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 2/2534 0% |
Mutation Distribution
Where KRTAP29-1 is mutated · all tissues, split by cell line vs tissue
How many mutations in KRTAP29-1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 10 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 105 mutations in KRTAP29-1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|